Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review by Zanetti, Andernice dos Santos et al.
Rev Inst Med Trop São Paulo. 2019;61:e42 Page 1 of 11
ORIGINAL ARTICLE
http://doi.org/10.1590/S1678-9946201961042
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
1Universidade do Estado de Mato Grosso, 
Faculdade de Ciências Agrárias e 
Biológicas, Programa de Pós-Graduação 
em Ciências Ambientais, Cáceres, Mato 
Grosso, Brazil
2Universidade Federal de Mato Grosso, 
Faculdade de Enfermagem, Programa de 
Pós-Graduação em Enfermagem, Cuiabá, 
Mato Grosso, Brazil
3Centro Brasileiro para o Cuidado à Saúde 
Informado por Evidências, Centro de 
Excelência do Instituto Joanna Briggs, São 
Paulo, São Paulo, Brazil
4Universidade de Cuiabá, Programa de 
Pós-Graduação em Ambiente e Saúde, 
Cuiabá, Mato Grosso, Brazil
5Universidade do Estado de Mato Grosso, 
Faculdade de Ciências da Saúde, 
Departamento de Medicina, Cáceres, Mato 
Grosso, Brazil
Correspondence to: Omar Ariel Espinosa 
Universidade do Estado de Mato Grosso, 
Faculdade de Ciências da Saúde, 
Departamento de Medicina, Av. Tancredo 
Neves, 1095, CEP 78200-000, Cáceres, 
MT, Brazil 
Tel: +55 65 3221-0000
E-mail: oespinosa@usp.br 
Received: 15 April 2019
Accepted: 15 July 2019
Diagnostic accuracy of Enzyme-Linked Immunosorbent 
Assays to detect anti-Leishmania antibodies in patients with 
American Tegumentary Leishmaniasis: a systematic review
Andernice dos Santos Zanetti1, Camila Massae Sato2, Fabiana Gulin Longhi3, 
Silvana Margarida Benevides Ferreira2,3,4, Omar Ariel Espinosa 5
ABSTRACT
American Tegumentary leishmaniasis (ATL) is an infectious disease caused by several 
species of Leishmania. Even though the direct detection of parasites has low sensitivity, it 
is still the gold standard for the laboratory diagnosis of ATL. Recent studies have shown 
promising results of Enzyme-Linked Immunosorbent Assays (ELISAs) using recombinant 
antigens. The aim of this study is to compare the accuracy of ELISAs using novel antigens 
with the standard ELISA based on soluble antigens of Leishmania (SLA) to diagnose ATL. 
Studies that analyzed patients with ATL and studies that evaluated the diagnostic accuracy of 
ELISAs using novel antigens and SLA were included. The Fourteen studies from PubMed, 
Regional Portal of the Virtual Health Library (BVS), Brazilian Society of Dermatology, 
Virtual Health Library (IBECS), Literature in the Health Sciences in Latin America and the 
Caribbean (LILACS), Medical Literature Analysis and Retrieval System Online (Medline), 
Elsevier Embase, Cochrane Library, The National Institute for Health and Care Excellence 
(NICE), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were 
included. The novel ELISA antigens showed a high sensitivity (93.8%-100%) and specificity 
(82.5-100%), a better diagnostic performance than SLA-based ELISAs (1-97.4% and 
57.5-100%, respectively). Only 10 studies analyzed cross-reactions in serum samples from 
patients with Chagas disease, and only two studies reported a percentage of cross-reactivity. 
In this systematic review, the novel ELISA antigens showed better sensitivity and specificity 
with respect to SLA-based ELISAs. However, a meta-analysis should be performed to 
confirm this finding. 
KEYWORDS: American Tegumentary Leishmaniasis. ELISA. Accuracy. Diagnosis. 
Serology. Recombinant antigens. Novel antigens. Leishmaniasis. 
INTRODUCTION
American Tegumentary Leishmaniasis (ATL) is an infectious disease that affects 
the skin and mucous membranes, showing distinct clinical manifestations determined 
by an equilibrium between parasitic factors (tropisms, virulence, resistance and 
species) and the host immune response1-3. The main clinical forms are cutaneous 
leishmaniasis (CL), muco-cutaneous leishmaniasis (MCL) and disseminated 
cutaneous leishmaniasis (DCL). The cutaneous leishmaniasis (CL) is caused by 
L. (V.) braziliensis, L. (V.) guyanensis, L. (L.) amazonensis and L. (V.) naiffi. The 
muco-cutaneous leishmaniasis (MCL) is caused by L. (V.) braziliensis and the 
disseminated cutaneous leishmaniasis (DCL) is caused by L. (L.) amazonensis and 
L. (L.) mexicana4.
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According to the World Health Organization (WHO), 
leishmaniasis is one of the most important neglected 
tropical diseases due to its high detection coefficient and 
capacity to produce deformities. This disease affects mainly 
individuals of low socioeconomic level, and the number of 
cases in endemic areas have increased significantly in recent 
years5-8. It is estimated that 350 million people are at risk 
of contracting the infection, and the annual incidence is 
estimated at about two million new cases9. 
In Brazil, about 20 thousand cases/year are recorded, with 
an incidence coefficient of 10.3 cases/100,000 inhabitants in 
the last five years. In 2015, the Brazilian North region had 
the highest incidence rate (51.1 cases/100,000 inhabitants), 
followed by the Midwest (19.0 cases/100,000 inhabitants) 
and the Northeast (9.1 cases/100,000 inhabitants)10. 
The diagnosis of leishmaniasis is based on 
epidemiological data, clinical characteristics and laboratory 
test results, including parasitological examination, 
serological and molecular methods as well as the 
Montenegro skin test4. 
Clinical practice guidelines recommend multiple 
testing of active cutaneous lesion samples. Thus, the 
parasitological diagnosis is based on the evidence of 
the parasite through direct microscopy of smears and/
or culture, requiring a trained laboratory staff11,12. In 
addition, these tests require invasive procedures of sample 
collection, which limit their use13. Even though the direct 
detection of parasites has low sensitivity, it is still the 
gold standard for the laboratory diagnosis of ATL. The 
Montenegro skin test (MST), with a sensitivity rate of 
86.4-100%14, is the main diagnostic test in primary care. 
In the presence of a suspicious cutaneous lesion, MST 
supports the diagnosis of Leishmania infections. However, 
MST results may be influenced by the clinical presentation 
and the disease duration14.
The association of MST with molecular biology 
methods, especially in reference treatment centers, offers 
higher diagnostic accuracy as well as good sensitivity and 
specificity. Therefore, a combination of diagnostic methods 
is usually required to obtain accurate results15,16. There is a 
need to develop faster, more effective and simpler assays for 
the diagnosis of this disease17. Among these tests, serology 
has been the most widely used method in epidemiological 
studies, providing additional support for disease control 
measures. However, since most patients have low antibody 
titers against Leishmania species, this method may be 
associated with a relatively high proportion of false negative 
results. In addition, different species of Leishmania overlap 
the distribution of Trypanosoma cruzi in many geographic 
regions, increasing the risk of cross-reactions in these 
endemic areas18,19.
ELISAs are useful diagnostic tools for ATL, being 
fast and relatively affordable. However, their accuracy is 
variable20,21. Several studies have selected proteins common 
to Leishmania species to develop an assay capable of 
detecting the disease irrespective of the etiological agent 
species. Among the proteins used, cytochrome c oxidase VII 
(CcOx), IgE-dependent histamine-releasing factor (HRF) 
and histones have been used21,22.
Recently, several recombinant proteins have been 
successfully developed and used for the serological 
diagnosis of ATL, showing better sensitivity and specificity. 
In ELISAs, the recombinant antigens rK108, rLbHyM, 
rLHHs, rHSPH83, RA2, rLb6H, and rLb8E were used23-27.
Promising results in several studies on ELISAs using 
recombinant antigens have been reported. The successful 
implementation of these methods reflects their good 
performance. Therefore, this study provides a brief 
systematic review of studies on the accuracy of available 
serological tests, aiming to evaluate the accuracy of these 
tests for the detection of antibodies against Leishmania 
species.
MATERIALS AND METHODS
The protocol of this systematic review was published 
in the International Prospective Record of Systematic 
Reviews (PROSPERO 2018: CRD42018114275) before 
its implementation and is described in the Complementary 
Materials. The protocol and the final report were developed 
based on the Cochrane Handbook for Systematic Reviews 
of Diagnostic Test Accuracy28.
Review question
What is the diagnostic accuracy of ELISAs with 
novel antigens compared to the standard serological test 
based on soluble antigens of Leishmania species (SLA) 
for the serological diagnosis of American Tegumentary 
Leishmaniasis (ATL)?
Inclusion and exclusion criteria
This review considered studies that included patients 
with ATL that were diagnosed by at least one of the 
parasitological gold standards (Montenegro skin test, direct 
microscopy of smears and/or culture) or by the Polymerase 
Chain Reaction (PCR). In addition, we included studies that 
evaluated the diagnostic accuracy of ELISAs based on novel 
antigens for the serological diagnosis of ATL, as well as 
those using soluble Leishmania antigens (SLA) in order to 
detect antibodies against species of Leishmania that cause 
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ATL. Studies that analyzed the accuracy of ELISAs but did 
not define the endemic controls were excluded. 
Types of study
Cross-sectional studies based on diagnosis by 
serological tests providing detailed measurements of 
sensitivity, specificity, positive and negative predictive 
values, likelihood ratio and area under the curve (AUC), 
were included.
Search strategy
An initial search limited to MEDLINE was performed 
by using the MeSH index terms and related keywords. 
This search was performed followed by the analysis of 
words along the text that were also mentioned in the titles 
and summaries and terms of the index used to describe the 
studies. A second search using all the identified keywords 
and index terms was performed on all included databases. 
In a third search, the reference list of all dissertation theses 
with clearly detailed accuracy values were evaluated. 
Considering that ATL is a disease that affects the American 
continent, the search was limited to English, Spanish and 
Portuguese. The search for primary literature was not 
limited to the initial date and was completed in October 
2018. 
The search for studies used the following databases: 
PubMed, Regional Portal of the Virtual Health Library 
(BVS), Brazilian Society of Dermatology, Virtual Health 
Library (IBECS), Literature in the Health Sciences in 
Latin America and the Caribbean (LILACS), Medical 
Literature Analysis and Retrieval System Online (Medline), 
Elsevier Embase, Cochrane Library, The National Institute 
for Health and Care Excellence (NICE), and Cumulative 
Index to Nursing and Allied Health Literature (CINAHL). 
The MeSH Index Terms searched were: Leishmaniasis, 
cutaneous Leishmaniasis, Mucocutaneous; ELISA; 
Serological, Test; Diagnosis; Leishmania; Serology; 
Data Accuracy. The keywords used were: “American 
Tegumentary Leishmaniasis, Serodiagnosis, Specificity 
and Sensitivity. The terms were combined via the boolean 
operators “AND” and/or “OR” to compose the search 
strings. 
Methodological quality assessment
The articles selected for data collection were read by 
two independent reviewers to evaluate the methodological 
validity of each text before their inclusion in this review. 
The standardized critical evaluation instrument QUADAS 2 
was used, which was released in 2011 after the revision of 
the original QUADAS (Quality Assessment of Diagnostic 
Accuracy Studies)29,30. All disagreements between reviewers 
were resolved through discussion or by a third reviewer.
Data extraction
Quantitative data were extracted from the texts 
included in this review using the STARD (Standards for 
Reporting Studies of Diagnostic Accuracy) checklist31. 
All disagreements between both reviewers were resolved 
through discussion or by a third reviewer.
Data synthesis
The results are shown in three groups: 1) Novel-based 
ELISA (novel antigens); 2) SLA-based ELISA (soluble 
antigens of Leishmania) and 3) immunofluorescence assays 
(IFA). The development of a meta-analysis to analyze the 
general performance of the tests was not performed as there 
was only one study for each ELISA based on a given novel 
antigen and also due to a great heterogeneity in the standard 
ELISA based on SLA. Data found in this study will be 
shown only in a narrative and qualitative way.
RESULTS
Our research resulted in 315 manuscripts related to 
the serology of leishmaniasis by the combined application 
of descriptors in the databases described above. Only 
14 studies remained (Table 1)20,22,24,25,27,32-40 after applying 
the eligibility criteria (duplicate texts, articles related to 
other topics, texts excluded due to review or quality method 
criteria). The studies evaluated the diagnostic accuracy 
of different specific and novel antigens. The function 
of some of these antigens are not known, for instance 
conserved hypothetical proteins such as rLiHyS, rLbHyM, 
LiHypA and LbrM.30.3350. Other antigens are heat shock 
proteins (HSP),rLb8E, rLb6H and HSP83.1, histamine-
releasing factor (HRF), cytochrome C oxidase VII (CcOx), 
tryparedoxin peroxidase, eukaryotic initiation factor 5a, 
enolase, and γ-Tubulin. These assays were compared to 
standard ELISAs using soluble antigens from different 
Leishmania species (SLA), enriched membrane fraction 
and indirect immunofluorescence (IFA) assays. The results 
of our search strategy are shown in a PRISMA flowchart 
(Figure 1).
The methodological quality assessment revealed that 
the studies included in this systematic review had a “low 
risk of bias” in the domains of patient selection, index test, 
reference standard as well as flow and timing. Regarding 
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the “applicability concerns,” the selected studies showed a 
low concern in the domains of patient selection, index test 
and reference standard (Figure 2). Data extracted from the 
final selection are shown in Table 2.
In the 14 studies included in this systematic review, 
2,478 ELISAs were distributed among 1,155 (46.6%) 
samples from patients with ATL, 870 (35.1%) were endemic 
controls and 453 (18.3%) analyses were evaluated cross-
reactions with serum samples from patients with Chagas 
disease. Only seven studies distributed the samples of 
patients with ATL according to the clinical form of the 
disease into the categories cutaneous leishmaniasis (CL) and 
muco-cutaneous leishmaniasis (MCL) (Table 1). Regarding 
the comparisons with IFA, 417 tests were performed in only 
two studies. It is important to mention that cross-reactions 
with other dermatological diseases were also analyzed in 
Table 1 - A summary of the included studies.
Journal Year Author 
Samples
EC CD
CL ML
Parasitol Int. 2018 Dias DS 0 23 35 235
Parasitol Res. 2017 Lima MP 20 25 25 10
Clin Microbiol. 2017 Sato CM 219 68 91
Cell Immunol. 2017 Carvalho AMRS 27 30 40 15
Vet Parasitol. 2016 Coelho EA 12 12 20 8
Clin Vaccine Immunol. 2015 Duarte MC 23 20 30 10
Braz J Infect Dis. 2015 Soares KA 98 80 24
Clin Vaccine Immunol. 2014 Menezes-Souza D 45 20 50 20
J Clin Lab Anal. 2010 Cataldo JI 76 76 0
Braz J Infect Dis. 2009 Szargiki R 87 13 10
J Clin Lab Anal. 2009 Nascimento LD 189 189 0
Trans R Soc Trop Med Hyg. 2009 Barroso-Freitas APT 74 20 92 0
Acta Trop. 2008 Vidigal C de P 48 48 30
Bol Malariol Salud Ambient. 2007 Añez N 87 104 0
EC = Endemic control; CD = Serum samples from Chagas Disease patients; NI = Not Included; CL = Cutaneous Leishmaniasis; 
ML = Mucosal Leishmaniasis. 
Figure 1 - A flowchart of the steps performed in the systematic review.
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Table 2 - PRISMA checklist.
Section/topic # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. Title
ABSTRACT 
Structured 
summary 2
Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number. 
Abstract
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. Introduction
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS). 
Introduction and 
Methods: 
Review Question. 
METHODS 
Protocol and 
registration 5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and if available, provide registration information including registration 
number. 
Methods
Eligibility criteria 6
Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale. 
Methods: 
Inclusion Criteria
Information 
sources 
7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last searched. 
Methods: 
Search Strategy
Search 8 Present full electronic search strategy for at least one database, including any limits 
used, so that that it could be repeated. 
Methods: 
Search Strategy
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review and, if applicable, included in the meta-analysis). 
Methods: 
Study Strategy
Data collection 
process 10
Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming the data obtained by 
investigators. 
Methods: 
Data extraction
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made. 
Methods: 
Data extraction/
Quality assessment
Risk of bias in 
individual studies 12
Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was performed in the study or outcome level), and how 
this information is to be used in any data synthesis. 
NA
Summary 
measures 
13 State the principal summary measures (e.g., risk ratio, difference in means). NA
Synthesis of 
results 14
Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis. NA
Risk of bias 
across studies 15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies). NA
Figure 2 - Assessment of methodological quality domains in all the studies. Proportions of studies rated as “high,” “unclear,” and 
“low” are presented.
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a few of the included studies (histoplasmosis, malaria, 
paracoccidioidomycosis, toxoplasmosis, tuberculosis, and 
leprosy). Regarding the geographic distribution, 89.6% of 
the samples were collected in Brazil and only 10.4% in 
Venezuela.
Synthesized measurements of accuracy
A global estimate of the accuracy of ELISAs used 
as serological methods in the diagnosis of ATL was 
summarized.
Based on recombinant antigens and other known 
proteins, novel antigens (HSP, rLb8E, rLb6H, HRF, 
LiHypA, CcOx, trypidoxin peroxidase, eukaryotic initiation 
factor 5, enolase and γ-tubulin) and standard SLA-based 
ELISAs were compared (Table 3).
In novel-based ELISAs, only four studies calculated the 
positive and negative predictive values (PPV and NPV), 
two calculated the likelihood ratio (LR), three calculated 
the percentage of accuracy and three the area under the 
curve (AUC). Regarding SLA-based ELISA tests, in nine 
studies, the positive and negative predictive values were 
calculated, the likelihood ratio by two, the percentage of 
accuracy by three and the AUC by two. Finally, in the two 
studies that compared IFA methods, the PPV and NPV were 
calculated (Table 3).
The novel-based ELISAs showed a sensitivity between 
93.8-100% and a specificity between 82.5-100%, with 
equally high confidence intervals (CI) of 95% (Figure 3). 
The PPV showed values between 98.3-100% and NPV was 
100% in the five studies that calculated these data. The 
accuracy percentage was between 90.4-100%, and the AUC 
values were between 0.989 -1. The LR values reported in 
two studies were 50 and 55 (Table 3).
The SLA-based ELISAs showed an inconsistent and 
poor performance, with a range of sensitivity between 
Section/topic # Checklist item Reported on page # 
Additional 
analyses 16
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified. 
Methods: 
Data Synthesis
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram. Results (Figure 1)
Study 
characteristics 18
For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations. Results (Table 1)
Risk of bias within 
studies 19
Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12). NA
Results of 
individual studies 20
For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot. 
Results:  
Figure 2 and 3
Synthesis of 
results 21
Present results of each meta-analysis done, including confidence intervals and 
measures of consistency. NA
Risk of bias 
across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). NA
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]). Results
DISCUSSION 
Summary of 
evidence 24
Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers). 
Discussion
Limitations 25 Discuss limitations at study and outcome levels (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Discussion
Conclusions 26 Provide a general interpretation of the results in the context of other evidence and implications for future research. Conclusion
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply 
of data); role of funders for the systematic review. NA
NA = Not Applicable. Data collected on Prisma42
Table 2 - PRISMA checklist.
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1-97.4%, and a specificity between 57.5-100%, with equally 
heterogeneous CI 95% (Figure 4). The PPV values ranged 
from 59- 100%and the NPV values ranged from 39.3-100%. 
The accuracy percentage ranged from 61.4-91.1% and the 
two AUC measured were 0.6 and 0.989. The reported LR 
values were 8.5 and 37.5% (Table 3).
A single study used Enriched Membrane Fraction and 
reported sensitivity and specificity of 89.5% and 93.4%, 
respectively. In addition, PPV (93.2%), NPV (89.9%), LR 
(13.6) and AUC (0.934) were also reported (Table 3).
Regarding the accuracy of SLA-based ELISAs by 
leishmania species, L. (V.) braziliensis antigens were the 
Figure 3 - Summary of sensitivity and specificity values of the novel-based ELISAs reported for each antigen.
Figure 4 - Summary of sensitivity and specificity values of standard ELISA assays based on soluble antigen of specific Leishmania 
species. Observation: the author did not specify the Leishmania specie used.
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and specificity, proving a better diagnostic performance 
than standard ELISAs (SLA), which showed heterogeneous 
values. However, the use of paired indicators (sensitivity 
and specificity) can create a bias when the performance of 
competing tests is performed, especially if one test does 
not outperform the other with respect to both indicators. 
Through a meta-analysis, the diagnostic odds ratio (DOR), 
which is the only indicator of diagnostic performance, 
would help to evaluate the diagnostic test performance in 
the studies objectively41. 
Regarding SLA, the soluble antigens of L. (V.) 
braziliensis showed a better performance than the soluble 
antigens of the other species used in the serological 
diagnosis of LTA. In IFA tests, sensitivity and specificity 
values were similar to those observed in standard ELISAs 
(SLA). This could be explained by the fact that both, 
SLA-based ELISAs and IFAs were developed using the 
same Leishmania species. 
From the total of 14 studies included in this systematic 
review, ten made comparisons on cross-reactions with serum 
samples from patients with Chagas disease, and only two 
reported the occurrence of cross-reactivity. The only novel-
based ELISA that reported cross-reactivity was developed 
using rLb6H27. This recombinant antigen had a reactivity of 
17%, which is lower when compared to the 69% observed 
in the SLA-based ELISA of L. major-like and 33% with L. 
(L.) mexicana. SLA-based ELISAs of L. amazonensis and L. 
braziliensis showed a lower or equal reactivity to rLb6H20. 
The percentage of cross-reactivity to serum samples 
from patients with Chagas disease, in the serological 
methods used for the diagnosis of ATL, should be reported 
to estimate or at least to be aware of the probability of a 
cross-reactivity. For this reason, when using tests that show 
a high percentage of cross-reactivity for the diagnosis of 
ATL, the possibility of a coinfection with T. cruzi cannot 
be ruled out. Any suspicion of coinfection should be 
investigated using specific Chagas disease tests.
Using the genome sequencing, we can calculate the 
percentage of similarity of a target protein sequence among 
species of Leishmania and Trypanosoma cruzi before they 
are used as antigen in ELISAs to save time and resources.
There are some limitations in our study. First, the novel 
antigens as well as soluble antigens of different species of 
Leishamnia are different, resulting in different cut-off values. 
Second, although the specificity was almost 100%, only a 
few authors included groups of control patients with diseases 
other than Chagas, such as tuberculosis, histoplasmosis, 
malaria and paracoccidioidomycosis. Finally, some studies 
included in this systematic review did not analyze positive 
and negative predictive values, and only a few showed 
values of likelihood ratio, area under the curve and accuracy. 
most used, showing values from 1- 95.7% of sensitivity and 
57.5- 100% of specificity. Two studies used L. (L.) major-
like and reported values of 85.4- 91.2% of sensitivity and 
82.8- 95.6% of specificity. L. (L.) mexicana 90.8-80.3%, 
L. (L.) amazonensis 71.7- 84.6% and L. (L.) infantum 
62-73%, respectively.
The IFA tests were performed using different species 
of Leishmania (L. braziliensis, L. major-Like, Bio-
Manguinhos commercial antigen and another that was 
not specified). Regarding the diagnostic performance of 
IFAs. These tests showed a sensitivity between 23- 95.4% 
and a specificity between 77.7- 89.2%. The PPV values 
ranged from 63.- 79.6% and the NPV values ranged from 
69- 96.9% (Table 3).
Cross-reactivity with Chagas disease
Ten studies performed comparisons of cross-reactions 
with serum samples from patients with Chagas disease, 
and only two reported reactivity (lack of specificity). 
Among the studies analyzing ELISAs with novel antigens, 
only one reported 17% (95% CI, 12-27.9) of reactivity in 
ELISAs based on the recombinant rLb6H antigen27. As for 
standard ELISAs based on SLA, several percentages of 
cross-reactivity were reported according to the species used: 
L. major-Like 69% (95% CI, 66.1 - 83.5)27, L. mexicana 
66.7%35, L. amazonensis 10% and L. braziliensis 20%36.
DISCUSSION
Our research shows data that point to a problem 
regarding the choice of serological methods for the 
diagnosis of ATL. Several ELISAs using different types 
of antigens, have been proposed as sensitive tools for the 
diagnosis of this disease. From the available literature, we 
analyzed and summarized data on diagnostic accuracy 
studies of ELISAs based on novel antigens, some of them 
recombinants. They were compared with standard ELISAs 
based on soluble Leishmania antigens (SLA). Due to the 
existence of only one study per novel antigen, a meta-
analysis was not conducted in this review as at least four 
studies are necessary to perform a meta-analysis. 
Our research question was restricted to the Americas 
aiming to produce useful evidence for ATL control 
programs in the region. Since 92.2% of ELISAs included 
in this systematic review were developed in Brazil and the 
remaining 7.8% in Venezuela, our results reflect the state 
of serological diagnostic tests for ATL in Brazil.
Several indicators of diagnostic performance were 
proposed, such as the percentage of sensitivity and 
specificity. Novel ELISA antigens showed a high sensitivity 
Zanetti et al.
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The lack of these data limited the comparison between the 
methods analyzed with regard to indicators such as sensitivity 
and specificity. Using paired indicators can be a disadvantage 
to compare the performance of competing tests, especially 
if one test does not outperform the other with respect to 
both indicators41. Both, sensitivity and specificity provide 
information about the probability of obtaining an accurate 
result (positive or negative) depending on the true condition 
of the patient with respect to the disease. However, PPV and 
NPV are useful in clinical practice informing the probability 
of the patient to be really sick or healthy according to a 
positive or negative result.
In this systematic review, the novel ELISAs antigens 
showed an advantage in sensitivity (95.4-100%) and 
specificity (82.5-100%) compared to standard ELISAs 
based on SLA (1%-97.4% and 57.5%-100%, respectively). 
These ELISAs based on SLA, together with IFAs showed 
heterogeneous accuracy values. 
The development of new serological diagnostic tools, 
with higher accuracy and reliability in the diagnosis of 
ATL and capable of reducing the risk of cross-reactivity 
with Chagas disease or other infectious diseases is of great 
importance for laboratory diagnosis, analysis of treatment 
efficacy, epidemiology and disease control.
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